Canaccord Genuity Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $110

Benzinga Newsdesk www.benzinga.com Positive 60.7%

Neg 0% Neu 0% Pos 60.7%

Canaccord Genuity analyst Gary Nachman initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy rating and announces Price Target of $110.